Key Highlights

● Inhibrx was among the steepest decliners in its sector.

● No company-specific news was found to explain the move.

● The stock trades on the Nasdaq and is tracked by the Russell 2000.

● Inhibrx develops protein-based antibody therapies for cancer.

Inhibrx Biosciences (NASDAQ:INBX) tumbled, but no company-specific news was found to explain the move. The stock was among the steepest decliners in a market live blog, which said it found no company news behind the drop.

Without an announcement from Inhibrx itself, the decline may reflect moves in its sector or the broader market rather than anything specific to the company.

A Volatile Day for Biotech

Small-cap biotech stocks swung sharply in both directions the same day. Bicara Therapeutics plunged with no company news found, and Rapport Therapeutics tumbled after pricing a stock offering, while other names such as Genmab jumped on Phase 3 cancer trial results.

Development-stage biotech stocks can move sharply without company news, since their valuations depend heavily on expectations about future trial results, and shifts in investor appetite for risk can lead to large swings, especially in thinly traded names.

What Inhibrx Does

Inhibrx Biosciences is a clinical-stage biotech that develops protein-based therapies, including engineered antibodies, targeting cancer and other serious diseases through designs intended to improve how drugs bind to their targets.

The current company was formed after its predecessor sold a rare-disease program and spun off its remaining pipeline into a new public company, which includes oncology candidates currently in clinical trials.